Method for treating cancer

Abstract

The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

We claim: 
     
         1 . A method for treating an INI1-negative tumor comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the INI1-negative tumor is selected from a rhabdoid tumor of the kidney (RTK) and an atypical teratoid/rhabdoid tumor (ATRT). 
     
     
         2 . The method of  claim 1 , wherein the INI1-negative tumor is rhabdoid tumor of the kidney (RTK). 
     
     
         3 . The method of  claim 1 , wherein the IM1-negative tumor is atypical teratoid/rhabdoid tumor (ATRT). 
     
     
         4 .- 6 . (canceled) 
     
     
         7 . The method of  claim 1 , wherein the EZH2 inhibitor is administered orally. 
     
     
         8 . The method of  claim 1 , wherein the subject is a human being. 
     
     
         9 . The method of  claim 1 , wherein the subject is younger than 18 years. 
     
     
         10 . The method of claim  19 , wherein the EZH2 inhibitor is Compound (A), having the following formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         11 . The method of  claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily. 
     
     
         12 . The method of  claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID to about 1600 mg BID. 
     
     
         13 . The method of  claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or about 1600 mg BID. 
     
     
         14 . The method of  claim 13 , wherein the EZH2 inhibitor is administered to the subject at a dose of 800 mg BID. 
     
     
         15 . The method of  claim 1 , wherein the EZH2 inhibitor is selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         16 . The method of  claim 15 , wherein the EZH2 inhibitor is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.